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Abstract
Osteoporosis is a complex disorder and commonly leads to fractures in elderly persons. Genome-wide association studies
(GWAS) have become an unbiased approach to identify variations in the genome that potentially affect health. However,
the genetic variants identified so far only explain a small proportion of the heritability for complex traits. Due to the modest
genetic effect size and inadequate power, true association signals may not be revealed based on a stringent genome-wide
significance threshold. Here, we take advantage of SNP and transcript arrays and integrate GWAS and expression signature
profiling relevant to the skeletal system in cellular and animal models to prioritize the discovery of novel candidate genes
for osteoporosis-related traits, including bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN), as well
as geometric indices of the hip (femoral neck-shaft angle, NSA; femoral neck length, NL; and narrow-neck width, NW). A
two-stage meta-analysis of GWAS from 7,633 Caucasian women and 3,657 men, revealed three novel loci associated with
osteoporosis-related traits, including chromosome 1p13.2 (RAP1A, p = 3.661028), 2q11.2 (TBC1D8), and 18q11.2 (OSBPL1A),
and confirmed a previously reported region near TNFRSF11B/OPG gene. We also prioritized 16 suggestive genome-wide
significant candidate genes based on their potential involvement in skeletal metabolism. Among them, 3 candidate genes
were associated with BMD in women. Notably, 2 out of these 3 genes (GPR177, p = 2.6610213; SOX6, p = 6.4610210)
associated with BMD in women have been successfully replicated in a large-scale meta-analysis of BMD, but none of the
non-prioritized candidates (associated with BMD) did. Our results support the concept of our prioritization strategy. In the
absence of direct biological support for identified genes, we highlighted the efficiency of subsequent functional
characterization using publicly available expression profiling relevant to the skeletal system in cellular or whole animal
models to prioritize candidate genes for further functional validation.
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Introduction
The feasibility of carrying out genome-wide association studies
(GWAS) has led to the rapid progression of the field of complex-
disease genetics over the past few years. Although the GWAS
approach has been successful in identifying novel candidate genes
leading to new discovery of pathways that are involved in the
pathophysiology of diseases, the genetic variants identified so far
only explain a small proportion of the heritability for complex
traits [1]. Due to the modest genetic effect size and inadequate
power to overcome the heterogeneity of genetic effects in meta-
analysis, true association signals may not be revealed based on a
stringent genome-wide significance threshold alone [2]. In
addition, the majority of the GWAS have not provided much
information beyond statistical signals to understand the genetic
architecture for those usually novel genes that have not been
studied for a particular trait/disease before. Thus, the necessity of
incorporating additional information when studying the GWAS
has become apparent. Expression profiling with gene signatures of
cellular models have been used to characterize gene’s involvement
in bone metabolism and disease processes. One such approach is
parathyroid hormone (PTH) stimulated osteoclastogenesis and
osteoblast maturation for osteoblastogenesis [3]. PTH indirectly
stimulated osteoclastogenesis via its receptors on osteoblasts, which
then signal to osteoclast precursors to stimulate osteoclastogenesis.
Impaired osteoblastic differentiation reduces bone formation and
causes severe osteoporosis in animals [4]. The TNFRSF11B/OPG
gene, a well-known candidate gene for osteoporosis, is involved in
osteoclastogenesis through the regulation of PTH [5]. Compared
to GWAS-identified candidate genes that do not show differential
expression in these cellular models, genes like TNFRSF11B/OPG
with differential expression are more likely to be involved in
skeletal metabolism and thus more likely to be truly associated
with osteoporosis. Given that the majority of the reported genome-
wide significant SNPs are in the intergenic or noncoding regions
[6], it is not clear which SNP/gene might be implicated as a causal
SNP/gene. Since intergenic or noncoding SNPs do not appear to
affect protein sequence, it is likely that these SNPs either are in
linkage disequilibrium with the causal variants or located within
the transcription regulation elements of nearby genes. The relative
quantification of gene transcripts may act as intermediate
phenotypes between genetic loci and the clinical phenotypes.
Expression quantitative trait loci (eQTL) analysis in specific tissues
is a valuable tool to identify potentially causal SNPs [7–10]. By
integration of genetic variants, transcriptome, and phenotypic
data, investigators have the potential to provide much-needed
support to prioritize the candidate susceptibility genes identified
from GWAS for further validation [11–13].
Previously, we conducted a pilot GWAS for osteoporosis-related
phenotypes in a small subset of the Framingham study participants
[14]. Osteoporosis is a skeletal disorder characterized by
compromised bone strength predisposing to an increased risk of
fracture. The heterogeneity of osteoporosis has both an environ-
mental and genetic basis. Although bone mineral density (BMD) is
frequently used in the diagnosis and prognosis of osteoporosis [15],
a growing body of evidence indicates that femoral geometry also
contributes importantly to hip fracture risk [16,17]. Both BMD
and hip geometry are strongly heritable, with heritability estimates
between 50% and 85% [18]. In an attempt to identify genes that
are involved in the regulation of bone health related phenotypes,
genetic linkage analyses [19,20], candidate gene association studies
[21] and recent GWAS [22–27] have been used to implicate
several loci and candidate genes, such as OPG/RANK/RANKL
[22–24,28], LRP5 [22,23,29], LRP4 [23], ESR1 [23,30], VDR [31],
and SP7 [24,25]. However, the majority of genes that contribute to
genetic susceptibility to osteoporosis remain to be elucidated.
Seeking to extend these initial observations, in the current study,
we first performed a large-scale GWAS analysis for BMD and hip
geometry in 2,038 women and 1,531 men from the Framingham
Osteoporosis Study using 550,000 SNPs, and then replicated the
top findings in 5,595 women and 2,126 men from two
independent cohorts of Caucasian individuals. We then prioritized
the genome-wide association findings by utilizing publicly
available experiments relevant to the skeletal system in cellular
or whole animal models, and provided supportive biological
information for future functional validation of their involvement in
bone metabolism. The expression experiments included (1) gene
signatures of a mouse embryo expression atlas and mouse cellular
models of osteoblastogenesis and PTH- stimulated osteoblasts; (2)
eQTL analysis in human primary osteoblasts, lymphocytes and
liver tissues; and (3) likelihood-based causality model selection
(LCMS) by integrating genetic variants, gene expression profiling,
and skeletal phenotypes in inbred mice to identify candidate genes
causally related to bone phenotypes. An overview of the study
design is provided in Figure 1.
Results
Stage I: GWAS in Framingham Osteoporosis Study
Significant differences of BMD and geometry indices were
found between men and women in the Framingham Study with p-
values ,0.001 (Table S1). Quantile-quantile plots of observed p-
GWAS and Expression Profiling for Osteoporosis
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values for single SNP association tests under additive genetic effect
models are shown in Figure 2. Except for the tail (likely comprising
true associations), the distributions of observed p-values did not
deviate from the null distribution, which rules out systematic bias
due to bad genotyping or population substructure in our study
samples. The estimated genome control lGC for each phenotype
ranged from 0.99 to 1.02. The regression coefficients analyzed
with and without adjusting for the PCs are highly correlated
(r = 0.95–0.98). Thus, we do not expect these principal compo-
nents to influence our results substantially. SNPs associated with
each phenotype at p-values ,1026 are listed in Table S2. For
women, the most significant association was found with neck width
(NW) for SNP rs16965654 (MAF=0.01) located 13Kb away from
the 59 upstream region of the WD repeat and SOCS box-containing 1
(WSB1) gene on chromosome 17q11.1 (p = 4.1561028). For men,
the most significant association was found with neck-shaft angle
(NSA) for SNP rs11573709 (MAF=0.23) located in intron 7 of the
RAD23 homolog B (RAD23B) gene on 9q31.2 (p= 2.3761027). We
also performed association tests by combining men and women
together. The most significant association was found with NW for
SNP rs16965654 (p= 6.89610210).
Stage II: Meta-Analysis
All genotyped SNPs (n=431–593 for sex-specific phenotypes) with
association test p-values ,1023 in Stage I were examined for
replication in the Rotterdam Study (both men and women) and
TwinsUK Study (women only). We performed meta-analyses by
combining results from the Framingham Study and Rotterdam Study
in men and all three cohorts in women. P-values ,4.361027 from
meta-analyses are considered as genome-wide significant associations
(See statistical methods section for details). We listed the most
significant SNP on each chromosome locus with meta-analysis p-
values,1026 in Table 1. The most significant association for men was
found with NSA for SNP rs2278729 located in the intron 4 ofTBC1D8
on chromosome 2q11.2 (p=1.4861027). SNP rs7227401 located in
intron 4 ofOSBPL1A (18q11.2) was found to be strongly associated with
NW (p=4.2261027) in men. The most significant association for
women from meta-analysis was found with LS BMD for SNP
rs2062375 located in the intergenic region of TNFRSF11B and
COLEC10 genes on chromosome 8q24.12 (p=2.68610211). SNP
rs494453 located in the intron 2 of RAP1A on chromosome 1p13.2 was
also strongly associated with NW (p=2.8061027). The association
became more significant for SNP rs494453 when combining women
and men together (p=3.661028). None of the above associated SNPs
are exonic coding SNPs. For SNPs listed in Table 1, no significant
heterogeneity across studies was found and the p-values (as well as
regression coefficients) were not changed with or without adjustment of
body weight. The quality scores of imputed SNPs in Table 1 were
.0.98 (IMPUTE confidence score) for the TwinsUK Study and
.0.84 (MACH variance ratio) for the Rotterdam Study.
eQTL in Multiple Human Tissues
Cis-eQTLs were analyzed for eight candidate genes located
within 500 kb in four genome-wide significant loci (Table 2). All
eight candidate genes were expressed in bone tissue estimated by
either expressed sequence tag (EST) in the CGAP EST cDNA
library (Figure S1) or human primary osteoblast samples (Table 2).
However, since transcripts were not presented on expression
arrays, expression of TBC1D8 was not available in human primary
osteoblast samples. P-values ,0.005 estimated by false discovery
rate (FDR) were considered as significant. SNP rs494453 was
found to be significantly associated with transcript levels of the
RAP1A gene. Allele C of rs494453 is in LD with allele A of
rs3767595 (haplotype). The haplotype CA was associated with
lower expression of RAP1A, but higher NW (stronger bone
structure) in women. We also performed eQTL analyses in human
lymphocytes and liver tissue. Expression level of the RAP1A gene
was not available for either lymphocytes or liver tissue. SNPs on
chromosome 2q11.2 (TBC1D8 and RLP31) and 8q24.12
(TNFRSF11B) loci were associated with gene expressions in
lymphocytes (Table 2). The most significant eSNP was found for
SNP rs2278729 (chromosome 2q11.2) with TBC1D8 expression in
lymphocytes (p = 2.58610210) and liver tissue (p,10216, Figure
S3). Allele A of rs2278729 was associated with smaller NSA in
men and also with lower expression of TBC1D8 transcript. The
same allele A was also associated with lower RPL31 expression in
lymphocytes and was marginally significant in osteoblasts.
Consistency between the direction of effect on transcript levels
in lymphocytes and LS BMD was observed for TNFRSF11B at the
chromosome 8q24.12 locus, which confirmed a previous report
that increased TNFRSF11B expression levels have been shown to
inhibit bone resorption [32]. A previous study also demonstrated
that alleles associated with decreased BMD were associated with
differential allelic expression of the TNFRSF11B in lymphocytes
[22]. However, we did not observe associations of genome-wide
significant SNPs in/near the TNFRSF11B gene region with
TNFRSF11B expression levels in human primary osteoblasts,
possible due to lack of power.
Mouse Expression Profiling Experiments
We investigated the candidate genes corresponding to the
genome-wide significant SNPs in 4 chromosomal regions by
looking at reported gene functions (including biological processes,
canonical pathways and organism processes in human and mouse),
microRNA targets and gene-related human diseases (Table S3).
Except for the TNFRSF11B gene, there were few additional data
regarding the potential biological significance of other candidate
genes being involved in skeletal development and bone remodel-
ing; therefore, we performed additional analyses on expression
profiles in animal experiments (Table 3). In experiment 1, we
Author Summary
BMD and hip geometry are two major predictors of
osteoporotic fractures, the most severe consequence of
osteoporosis in elderly persons. We performed sex-specific
genome-wide association studies (GWAS) for BMD at the
lumbar spine and femor neck skeletal sites as well as hip
geometric indices (NSA, NL, and NW) in the Framingham
Osteoporosis Study and then replicated the top findings in
two independent studies. Three novel loci were significant:
in women, including chromosome 1p13.2 (RAP1A) for NW;
in men, 2q11.2 (TBC1D8) for NSA and 18q11.2 (OSBPL1A)
for NW. We confirmed a previously reported region on
8q24.12 (TNFRSF11B/OPG) for lumbar spine BMD in
women. In addition, we integrated GWAS signals with
eQTL in several tissues and publicly available expression
signature profiling in cellular and whole-animal models,
and prioritized 16 candidate genes/loci based on their
potential involvement in skeletal metabolism. Among
three prioritized loci (GPR177, SOX6, and CASR genes)
associated with BMD in women, GPR177 and SOX6 have
been successfully replicated later in a large-scale meta-
analysis, but none of the non-prioritized candidates
(associated with BMD) did. Our results support the concept
of using expression profiling to support the candidacy of
suggestive GWAS signals that may contain important
genes of interest.
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found that PTH negatively regulated expressions of OSBPL1A and
TNFRSF11B. RPL31, IMPACT and RAP1A genes were expressed in
PTH stimulated osteoblasts, but not regulated by PTH. TBC1D8
were not expressed in PTH stimulated osteoblasts. In experiment
2, we analyzed the differential expression of candidates during
osteoblast maturation. As a quality control measure, we looked at
a number of known osteoblast markers, including runt-related
transcription factor 2 (Runx2), collagen type 1, alpha 1 (Col1a1),
collagen type 1, alpha 2 (Col1a2), osteocalcin, osteopontin and
osteonectin. The expected expression patterns (differential expres-
sion during maturation) were observed in all cases. We observed
that the expression of OSBPL1A, IMPACT and COLEC10 was
Figure 1. Study design. A four-stage approach was applied. We first performed genome-wide association analyses of the BMD and hip geometry
traits in the Framingham Osteoporosis Study as a discovery stage (I) and replicated the top findings by meta-analysis (II), with a subsequent
assessment of the functional relevance of the replicated findings (III and IV).
doi:10.1371/journal.pgen.1000977.g001
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significantly different across a time course (Day 4, 5, 6, 8, 16, 25
and 30 post-differentiation) of osteoblast development (p,0.0083).
In the third experiment using the LCMS algorithm in the
B6XC3H F2 intercross mice, we found that OSBPL1A, IMPACT,
RAP1A and COLEC10 genes were predicted to be causally linked
with bone phenotypes (detailed phenotypes listed in Table S4)
based on the evidence of significantly pleiotropic effects on trait
QTL and eQTL.
Prioritization of the Genome-Wide Suggestive Candidate
Genes
A total of 109 suggestive genome-wide associated regions/genes
(most significant SNP with meta-analysis 4.361027, p-value #
561025) were selected based on the criteria that p-values showed
nominal association in the Framingham, Rotterdam and Twin-
sUK studies. Among them, 16 candidate genes were prioritized
with results either involving the differential expression in
osteoblasts or causally linked (LCMS algorithm) with bone
phenotypes in mice (Table 4). Among 16 prioritized candidate
genes/loci, PPAP2B, GPR177, TGFBI, DOCK1, SOX6 and PDGFD
gene expressions were regulated by PTH in osteoblasts. Significant
differential expression during osteoblast development was found
for GPR177, TGFBI, SOX6 and CDH2 genes. IRX2, TGFBI and
CDH2 genes showed strong expression in the skeleton compared to
24 other subsets of organ/tissue systems of the mouse embryo.
Using the LCMS algorithm in inbred mice, 12 genes were
predicted to be causally linked with bone phenotypes (detailed
phenotypes listed in Table S4). All of the prioritized candidate
genes are expressed in bone tissues. 10 genes were found to be
expressed in human bone tissue from the CGAP EST cDNA
library (Figure S1) and the remained genes (HECW2, CASR,
MMRN1, IRX2, SOX6 and SALL1) were found to be expressed in
human primary osteoblasts.
Gene Set Enrichment Test
To test the probability of our candidate genes clustering into a
particular biological pathway, we performed a gene set enrichment
test on 24 candidate genes (20 loci) from Table 2 and Table 4. Due
Figure 2. Quantile-Quantile plots for BMD and HSA in additive genetic models. The distributions of observed p-values did not deviate from
the null distribution, which rules out systematic bias due to bad genotyping or population substructure in our study samples.
doi:10.1371/journal.pgen.1000977.g002
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to lack of biological or functional annotation, IRX2 and FBXO31
genes were excluded from analyses. We found a significant
clustering (Fisher exact test p = 1.6561024; Benjamini-Hochberg
multiple testing corrected p-value = 0.03) of genes involved in
adhesion of cells, including CASR, CDH2, PPAP2B, RAP1A, TGFBI
and TNFRSF11B genes. We also estimated expression abundance
by number of expressed sequence tag (EST) sequences per 200,000
tags in the CGAP EST cDNA library for these 24 candidate genes.
Among 48 human tissues and organs, candidate genes were
expressed in bone (17 candidate genes), liver (22 candidate genes),
muscle (18) and adipose tissue (12) (Figure S1 and Figure S2).
Expression levels of RAP1A (p = 2.5161024), RPL31
(p = 3.0361027) and TNFRSF11B (p = 1.6961023) genes showed
over-representation in bone (Figure S1).
Discussion
In this study we performed sex-specific genome-wide association
studies for BMD at the LS and FN skeletal sites as well as
geometric indices of the hip in adults from the Framingham
Table 2. Cis-expression quantitative trait locus analyses of genome-wide significant SNPs (p , 4.3 x 10-7) selected from Table 1
with transcript levels in human lymphocytes and primary osteoblasts.
Target
SNP
Allele, Effect
direction Genea
Nearby
Transcripts
Distance to
transcript (Kb) Lymphocytes
b Primary osteoblastsc
P-value
Effect
direction
Surrogate
SNPs
r2, Distance (Kb)
to transcript P-value
Alleled, Effect
direction
rs2278729 G -. A, - TBC1D8 TBC1D8 Intron 4 2.58E-10 - rs6543018 0.75, Intron 1 n.a. n.a.
RPL31 32.7 1.11E-16 - rs6543018 0.75, 92.7 4.06E-02 T -. C, -
rs7227401 G -. T, + OSBPL1A OSBPL1A Intron 4 n.s. n.s. rs7226913 1.00, Intron 4 5.69E-01 C -. T, +
IMPACT 68.0 8.70E-03 - rs7226913 1.00, 68.3 6.71E-01 C -. T, +
rs494453 T -. C, + RAP1A RAP1A Intron 2 n.a. n.a. rs3767595 0.61, Intron 2 3.98E-03 G -. A, -
ADORA3 150.1 n.s. n.s. rs10489469 0.51, 32.3 3.11E-02 G -. T, +
rs2062375 C -. G, + TNFRSF11B TNFRSF11B 13.4 6.53E-06 + rs1032128 0.84, 21.9 2.47E-01 A -. G, -
COLEC10 101.7 n.s n.s. rs6469804 0.91, 5.2 8.20E-01 A -. G, -
a TNFRSF11B: The most significantly associated SNP located on the intergenic regions, the closest nearby gene was selected.
b Dataset with available imputed SNPs.
c Dataset without available imputed SNPs. Surrogate SNPs for the target SNP was used. r2 was estimated between target SNP and surrogate SNP.
b,c Experiments were performed in different study populations.
d The first allele is in LD with the major allele of the target SNP (haplotype). For example: Allele G of SNP rs2278729 is in LD with the allele T of rs6543018.
n.s. P-value . 0.005 (FDR).
n.a. Expression level was not available, since transcripts were not present on expression arrays.
doi:10.1371/journal.pgen.1000977.t002
Table 1. The most significant SNP in each locus with joint-analysis p-value ,1026.
SNP Allele
Cyto-
genetic
Loci Position Genea
Locationb/
Distance
(Kbps) to
nearby
gene Traitc Framingham Replication P-values
d,e Meta-analysisf
MAF Beta P-value Rotterdam TwinsUK
Meta
P-value
Effect
direction P-value
Men
rs2278729 G -. A 2q11.2 101035289 TBC1D8 Intron 4 NSA 0.33 -0.19 3.07E-06 5.19E-03e n.a. 5.19E-03 - - 1.48E-07
rs12808199 A -. G 11p12 39284535 LRRC4C* 987.7 FN BMD 0.43 -0.21 2.06E-05 3.88E-03 n.a. 3.88E-03 - - 8.89E-07
rs7227401 G -. T 18q11.2 20192656 OSBPL1A Intron 4 NW 0.39 0.17 3.58E-06 8.57E-03e n.a. 8.57E-03 + + 4.22E-07
Women
rs494453 T -. C 1p13.2 111993645 RAP1A Intron 2 NW 0.24 0.14 2.19E-04 3.28E-04e 2.59E-01e 2.77E-04 + + + 2.80E-07
rs12151790 G -. A 2q37.1 234875466 SPP2* 251.4 FN BMD 0.04 0.40 1.88E-06 1.60E-02e 4.52E-01e 2.58E-02 + + + 4.64E-07
rs2062375 C -. G 8q24.12 120046973 TNFRSF11B* 13.4 LS BMD 0.45 0.14 8.07E-06 1.59E-03e 4.58E-05e 2.47E-07 + + + 2.68E-11
rs17184557 T -. A 18q22.2 65293837 DOK6 Intron 1 LS BMD 0.23 0.13 9.19E-04 1.62E-02e 3.13E-03e 1.45E-04 + + + 8.81E-07
a SNP locates within a gene. *: For most significantly associated SNP located on the intergenic regions, the closest nearby gene was listed.
b The SNP location is shown if SNP locates within a gene. The distance (Kb) from an intergenic SNP to the closest gene is shown if SNP locates in the intergenic regions.
c NL: Neck Length; NW: Neck Width; NSA: Neck Shaft Angle.
d In men, data were only available from Framingham and Rotterdam studies. Meta-analysis p-values of the replication in men are the p-values from Rotterdam Study.
e Imputed SNPs: IMPUTE confidence score . 0.98 for TwinsUK; MACH variance ratio . 0.84 for Rotterdam Study.
f Effect direction: In the order of Framingham, Rotterdam and TwinsUK studies.
doi:10.1371/journal.pgen.1000977.t001
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Osteoporosis Study and then replicated the top finding in two
independent studies. As a result of meta-analyses on 7,633 women
and 3,657 men, we discovered three novel genome-wide
significant loci, including chromosome 1p13.2 RAP1A locus
(p = 3.6261028; NW in men and women combined), 2q11.2
TBC1D8 locus (p = 1.4861027, NSA in men) and 18q11.2
OSBPL1A locus (p = 4.2261027, NW in men). We also confirmed
TNFRSF11B gene on chromosome 8q24.12 to be associated with
LS BMD in women only (p = 2.68610211).
The RAP1A gene (chromosome 1p13.2) was predicted to be
causally linked with bone phenotypes in B6xC3H F2 intercross
mice. Compared to other tissues, expression levels of RAP1A
showed over-representation in human bone tissue. An eSNP
(rs494453) located in intron 2 of RAP1A gene was also found to be
significantly associated with RAP1A gene expression in human
primary osteoblasts. A marginally significant differential expres-
sion during osteoblast maturation was also found in our study.
RAP1A, a GTPase that mediates calcium signal transduction, has
been found to mediate activities of JnK [33]. JnK has been
reported to be involved in late stage osteoblast differentiation [34]
and apoptosis of osteoblasts [35]. Therefore, variants in the RAP1A
gene may change the activities of JnK and then impact osteoblast
maturation. Further experiments are necessary to explore the role
of the RAP1A gene. Both OSBPL1A and IMPACT genes located in
chromosome 18q11.2 region were predicted to be causally linked
with bone phenotypes in mice. Expressions of both genes were
found to be significantly differential during osteoblast maturation.
However, only expression of the OSBPL1A gene in osteoblasts was
regulated by PTH. No significant eQTL was found in this region.
Given the genome-wide significant SNPs were located in the
OSBPL1A gene, we still cannot rule out the involvment of the
nearby IMPACT gene. In addition, an in vitro study has shown that
DDIT3 over-expression enhances osteoblastic differentiation in
ST-2 stromal cells, a mechanism that may involve the formation of
heterodimers with C/EBP-b and the sensitization of the BMP/
Smad signaling pathway [36]. IMPACT protein has found to
decrease expression of mouse DDIT3 protein [37]; therefore,
IMPACT may negatively regulate bone formation.
We estimated the statistical power of our meta-analysis at an a-
level of 1027. In women, the power was 62–99% and .80% for
effect size (h2) equal to 1% and 2%, respectively. In men, the
statistical power was 35–75% and .70% for effect size equal to
1% and 2%, respectively. Inadequate statistical power seems to
be one of the limitations in our study. Therefore, we prioritized
16 candidate genes/loci out of 109 suggestive genome-wide
suggestive candidate genes (4.361027,p#561025) based on the
expression profiling and the LCMS modeling relevant to the
skeletal system. Among 16 prioritized candidate genes/loci,
PPAP2B, GPR177, SOX6 and CDH2 genes have been reported
to be involved in Wnt-signaling. CASR, TGFBI and CACNB2
genes are involved in ossification, endochondrial bone formation
in cartilage and calcium ion transportation, respectively (Table
S5). CASR knockout mice have demonstrated decreased bone
density and abnormal bone mineralization [38]. Variants in
GPR177, SOX6 and CASR genes were associated with LSBMD in
women. Variants in GPR177 and SOX6 (2 out of 3 above genes)
have been successfully replicated in a large-scale meta-analysis of
BMD on 19,195 Caucasian subjects (majority of whom were
women) with association p-values ,1029 [27], but none of the
non-prioritized candidates (associated with BMD) did. These
results support the concept of our prioritization strategy.
Candidate gene/SNP prioritization strategies by gene expression
and bioinformatic databases leverage the complexity of the
disease phenotypes, which offers some advantages over tradition-
al association studies that rely on strictly p-value driven
approaches. A recent study demonstrated that using functional
information in published references to identify the key biological
relationships between genes was able to predict the success of
validation in replication genotyping [39], which also provides
additional evidence for the soundness of using biological
Table 3. Expression profiles for 4 genome-wide significant loci in mice osteoblast gene expression experiments and Likelihood-
based Causality Model Selection (LCMS) regulatory network analysis in inbred mice.
Cytogenetic Loci The closest Genea Nearby Transcriptsb Experiment 1
c Experiment 2d Experiment 3e
PTH stimulated
primary osteoblasts
Differential expression during
osteoblast development
LCMS analysis for significant
eQTL and trait QTL pairs
Expression, Direction P-value # Traits Max # pairs
2q11.2 TBC1D8 TBC1D8 0 8.23E-01 0 0
RPL31 ++ n.a. n.a. n.a.
18q11.2 OSBPL1A OSBPL1A +++ Q 4.59E-03 1 2
IMPACT ++ 3.17E-03 1 2
1p13.2 RAP1A RAP1A ++ 2.12E-02 3 3
ADORA3 n.a. n.a. 0 0
8q24.12 TNFRSF11B* TNFRSF11B +++ Q 7.61E-01 0 0
COLEC10* COLEC10 n.a. 1.54E-03 1 2
a SNP locates within a gene. *: For most significantly associated SNP located on the intergenic regions, the closest nearby gene was listed.
b Transcripts: Transcripts from (1) the closest gene; or (2) genes with target SNP located less than 500K bps on the 5’ upstream flanking region.
c PTH stimulated primary osteoblasts: 0: not expressed; ++: expression level . 100 in all 3 replicates; +++: expressed in all 3 replicates and regulated by PTH.
d ANOVA was used to test the differential expression across 7 time points (Day 4, 5, 6, 8, 16, 25 and 30 post-induction) during osteoblast development. Bold: p-value ,
0.0083 ( = 0.05/6 available transcripts).
e LCMS analysis: Likelihood-based Causality Model Selection to predict candidate genes causally linked with bone phenotypes. Six bone related traits were tested. For
each trait test, at least 2 significant pleiotropy of eQTL and trait QTL pairs was considered evidence for a causally relation to the candidate gene.
c,d,e Results of experiment 1,2 and 3 were obtained from different mice strains and different laboratories.
n.a. Expression level is not available, since transcript is not presented on expression arrays.
doi:10.1371/journal.pgen.1000977.t003
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functional relevance to prioritize candidate genes from GWAS
for future validation.
We exploited eSNP/eQTL in multiple human tissues. Given
that (1) disease-related human tissues are often difficult to obtain
for research purposes; (2) eQTL analysis requires a large sample
size to reach the statistical power necessary to observe subtle
changes in gene expression [40]; and (3) all of the selected
candidate genes were expressed in bone tissues, we believe that
performing eQTL in multiple tissues, although not replacing
eQTL analysis in bone tissue, does provide complementary
information. Genetic control of biological functions may be
tissue-specific. Analysis of cis- eQTL in the tissue type directly
relevant to the phenotype has been generally shown to be more
informative than the same analysis in unrelated tissue types (such
as blood). However, studies have found that cis-eQTLs are
conserved across tissues, when genes are actively expressed in
those tissues [10,12,13,41–44]. eQTL analyses in liver, adipose,
brain and muscle tissues from the same individual mice suggested
that, for a gene exhibiting significant cis-eQTL associations in one
tissue, 63–88% (dependent on tissue types) of them also exhibit cis-
eQTL associations in another tissue [42]. Two recent studies,
quantifying allele-specific gene expression in four human cell lines
(lymphoblastoid cell, two primary fibroblasts and primary
keratinocytes) from the same individuals, observed that only 2.3–
10% of the mRNA-associated SNPs showed tissue-specific cis-
expression across these cell lines [43,44]. They also found that the
variation of allelic ratios in gene expression among different cell
lines was primarily explained by genetic variations, much more so
than by specific tissue types or growth conditions [43]. Among the
highly heritable transcripts (within the upper 25th percentile for
heritability), 70% of expression transcripts that had a significant
cis-eQTL in adipose tissue also had a significant cis-eQTL in blood
cells [45]. Comparing eQTL in human primary fibroblasts,
Epstein-Barr virus-immortalized B cells and T cells revealed that
cell-type-shared eQTL tend to have larger effects, higher
significance and to cluster tightly around the transcription start
site [46]. As for bone tissue, comparing gene expression in 58
human primary osteoblast samples and 57 lymphoblastoid cell
samples, despite tissues obtained from different individuals,
indicated that overall, there is a large overlap in genes expressed
in these two cell types, as well as the associated functional
pathways [47]. 60% of the top 100 eSNP in human lymphoblas-
toid cells also showed associations in human primary osteoblasts,
which indicated that both tissue-independent and dependent
eSNP were observed in primary osteoblasts and lymphoblastoid
cells [47]. Taken together this evidence suggests that if genes are
expressed across tissues, their allele-specific expression can be
preserved and highly correlated across tissues. Thus, the
expression of a gene in liver or other non-bone tissues may not
directly cause a change in bone; however, it is possible that its
allele-specific expression in liver is highly correlated with allele-
specific expression in bone. Because of these correlations it is
possible that a gene’s expression in adipose or liver can serve as
surrogate markers to study the eQTL; however, the real causal
relationship would be occurring in bone.
It is important to note that a lack of evidence from mining
publicly available gene expression experiments does not necessar-
ily exclude a gene’s involvment in skeletal metabolism, given that
(1) experimental models such as osteoblastogenesis or early skeletal
development, do not represent all relevant processes related to
osteoporosis; (2) variation in a gene leading to disease may affect
protein function but not expression; and (3) absence of association
between a transcript and disease-associated SNP may be due to
limited statistical power or under different environmental
a
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conditions. An inherent limitation in most of the cell line in-vitro
gene expression profiling experiments, such as our PTH treated
osteoblasts or Epstein-Barr virus-immortalized lymphoblastoid cell
lines used to perform eQTL analysis in most of the GWAS, is that
the expression profiling of the cultured cells may be varying from
actual expression within in-vivo cells [10]. An additonal challenge
of using available experimental data is that most of the studies
performed gene profing using commercialized ‘‘genome-wide’’
chips, which usually have a fixed number of genes and often do
not include all set of genes of given interest. Therefore,
prioritization of candidate genes will be biased towards well-
studied genes.
Few published GWAS have addressed the potential sex-
difference in genetic risks of diseases. BMD and hip geometry
for men and women are known to differ, as does the prevalence of
osteoporotic fractures [48]. Gender differences in the heritability
of osteoporosis-related phenotypes have been reported (reviewed
in [49]). In the current study, few overlapping associated SNPs
between men and women were found, which may be expected
based on epidemiological and clinical data and may also be due to
lack of power. Sex-specific associations may be due to lifestyle and
environmental variation between men and women. However, it
also indicates that common genetic effects for both genders may be
relatively rare and therefore, larger sample sizes of men and
women is needed to detect their existence. Another limitation is
that we are unable to distinguish the gender-specific differential
expressions, since gene expression is measured in a pooled mixture
of osteoblasts from males and females, although, differentiated
expression between sexes is actually less likely to occur in-vitro.
In summary, our study identified three novel genome-wide
significant loci and prioritized 16 genome-wide suggestive
candidate genes for BMD and hip geometry traits. Beyond
generating a list of top associated SNPs by statistical signals, we
highlighted the efficiency of our approach to reasonably prioritize
association findings by utilizing publicly available expression
profiling relevant to the skeletal system in cellular or whole animal
models; and to provide supportive biological information for
future functional validation of their involvements in bone
metabolism. Resequencing of these loci is needed to determine
the causal variants and genes, along with experimental functional
studies to establish their precise mechanism linked to bone health
related phenotypes.
Materials and Methods
A four-stage approach was applied (Figure 1). We first
performed genome-wide association analyses of the BMD and
hip geometry traits in the Framingham Osteoporosis Study
(discovery stage I) and replicated SNPs with association test
p,1023 using meta-analysis by combining results from the
Rotterdam Study, TwinsUK Study and Framingham Study (Stage
II), with a subsequent assessment of the functional relevance of the
replicated findings (Stage III and IV). All study subjects were of
self-reported Caucasian origin.
Discovery Stage (I)
Framingham Osteoporosis Study. The Framingham
Osteoporosis Study (FOS) is an ancillary study of the
Framingham Heart Study (FHS) [50]. The current study
involved participants from the FHS Original Cohort [51] and
Offspring Cohort [52]. The Original Cohort participants
underwent bone densitometry by DXA with a Lunar DPX-L
(Lunar Corp., Madison, WI, USA) during their examination 22
(1992–1993) and examination 24 (1996–1997). The Offspring
Cohort was scanned with the same machine at or between their
examination cycle 6 or 7 (between 1996 and 2001). Participants in
current study were a subset from the Original and Offspring
cohorts who provided blood samples for DNA and had DXA scans
of the hip and spine. Other than being selected on the basis of
having bone phenotypes and DNA, the participants were not
selected on any trait. In total, 2,038 females and 1,531 males had
both available genotyping and bone phenotypes (Table S1).
Informed consent was obtained from participants before entry into
the study. This study was approved by the Institutional Review
Boards for Human Subjects Research at Boston University and
the Hebrew Rehabilitation Center.
Quantitative bone phenotypes and covariates. Femoral
neck (FN) and L2–L4 lumbar spine (LS) BMD (g/cm2) was
measured by DXA with a Lunar DPX-L for all FOS participants.
The coefficients of variation (CV) in normal subjects for the DPX-
L have been previously reported to be 0.9% for the LS and 1.7%
for the FN BMD [50]. A hip structure analysis computer program
(HSA) [53] was used to derive a number of hip geometry variables
from the femoral DXA scans. The regions assessed were the
narrowest width of the femoral neck (NN), which overlaps or is
proximal to the standard Lunar femoral neck region. Although the
program derived a number of structural variables, in the current
study we only performed analyses for femoral neck length (NL,
cm), neck-shaft angle (NSA), as well as subperiosteal diameter
(neck width, NW, cm), which are direct measurements
independent of the DXA machines (Figure 3). The maximum
coefficients of variation were previously reported to be 4.2%, 1.8%
and 2.6%, respectively for NL, NSA and NW [54]. Covariates
potentially influencing BMD and hip geometry were obtained at
the time of DXA measurements along with an overall medical
history. Details of these measurements have been reported
previously [50]. These variables included age, sex, height,
weight, and estrogen use/menopausal status (for women). Each
woman was assigned to one of two estrogenic status groups: 1)
premenopausal or postmenopausal on estrogen replacement
therapy (estrogen-replete) or 2) postmenopausal not on estrogen
(estrogen-deplete) where menopause was defined as having no
menstrual period for at least one year.
Genotyping and exclusion of SNPs. Genotyping was
conducted by the FHS SHARe (SNP Health Association
Resource) project, for which 549,827 SNPs (Affymetrix 500K
mapping array plus Affymetrix 50K gene center array) were
genotyped in over 9,274 FHS subjects from over 900 families [55].
By estimation, we expected 80% genomic coverage (pair-wise
genotype correlation r2.0.8) of the HapMap Phase I+II common
SNPs (minor allele frequency, MAF $0.05) for the Caucasian
population [56]. We excluded 793 individuals with an average
SNP call rate ,0.97. We also excluded SNPs with call rate ,0.95
(34,868 SNPs; 6.3%); Hardy-Weinberg equilibrium (HWE) test p-
value ,1026 (8,531 SNPs; 1.6%); MAF ,0.01 (66,829 SNPs;
12.2%); or unknown genomic annotation (6,089 SNPs; 1.1%).
Ultimately, 433,510 SNPs were used in the genome-wide analyses.
Population substructure. Principal components analysis
(PCA) was used to estimate population substructure in
Framingham Study. We first applied PCA by EIGENSTRAT
[57] to all available genotypic data to infer continuous axes of
genetic variation (principal components, PCs) describing ancestral
heterogeneity (top eigenvectors of a covariance matrix). Since the
Framingham Study is family-based, the top 10 PCs were first built
using a subset of 200 biologically unrelated subjects and projected
to all study samples. The first two PCs showed gradients similar to
those previously reported in individuals of European ancestry,
such as northwest, southeast European and Ashkenazi Jewish [58].
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Next, we assessed the association between top 10 PCs and each of
the 5 phenotypes using regression models to examine if PCs were
significantly associated with each phenotype with adjustment of
age, sex, cohort, height and BMI. The top 4 PCs, PC1 to PC4
were all associated with FNBMD, LSBMD and NL at nominal p-
values less than 0.05. However, the top 4 PCs together only
Figure 3. Hip geometry indices. Red arrows indicate three hip geometry indices in a typical DXA image of the right hip. NL: Femoral neck length
(cm); NW: Narrow neck width (cm); and NSA: Neck-shaft angle.
doi:10.1371/journal.pgen.1000977.g003
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accounted for 0.1,0.7% of the variation in phenotypes. PCs were
not significantly associated with NW and NSA. To account for
potential population substructure in the SNP-phenotype
association tests in Framingham Study, we adjusted PC1 to PC4
along with other covariates in the mixed effect regression models.
Statistical analysis. Sex- and cohort (Original and
Offspring)-specific standardized residuals (mean= 0; SD=1) of
phenotypes were calculated using multivariate regression. For
BMD phenotypes, the covariates adjusted in the regression models
included PC1–PC4, age, age2 and estrogenic status (in women
only). For hip geometry, the covariates included height, BMI,
PC1–PC4, age, age2 and estrogenic status (in women only). Age2
was considered in the models to account for potential non-linear
age effects. These residuals were used in association analyses
described below. We performed both sex-specific and combined-
sexes GWAS using linear mixed effects regression models (LME),
with fixed SNP genotype effects, and random individual effects
that correlate within pedigree according to kinship relationship
[59]. The R package KINSHIP was used in the analyses.
Although LME accounts for the within family correlation, like
any population-based test for association, LME is sensitive to
population admixture; therefore, PC adjusted residuals were used.
Single SNP association tests were performed, using an additive
genetic effect model that estimated the effect of one copy
increment of the minor allele. To estimate how well the
distribution was calibrated, for each phenotype, we estimated
the genomic inflation factor (lGC) based on the median chi-
squared test of all study participants [60].
Replication Stage (II)
Joint analysis for results from both discovery and replication
stages almost always results in greater power than analyzing
discovery and replication stages separately [61]. We selected SNPs
with association test p-values less than 1023 from Stage I discovery
GWAS, and replicated them using meta-analysis by combining
results from the Framingham Study and two independent
population-based cohorts including the Rotterdam Study and
the TwinsUK Study. Since both the Rotterdam and TwinsUK
studies performed whole-genome genotyping using different
platforms (Illumina platforms), SNP imputation was performed.
Fixed effect meta-analyses were then used to estimate combined
p-values.
Rotterdam Study. The Rotterdam Study is a prospective
population-based cohort study of chronic disabling conditions in
Dutch elderly individuals aged 55 years and over [62]. Microarray
genotyping was performed in the whole original Rotterdam Study
cohort using the Infinium II HumanHap550K Genotyping
BeadChip version 3 (Illumina). The detail of genotyping
procedures and quality control was reported elsewhere [27]. For
population substructure, 102 individuals (.3 standard deviations)
and 129 individuals (.97% probabilities) deviating from
population mean of the IBS clustering [63] were excluded from
association analysis. MACH [64,65] was used to impute all
autosomal SNPs from the HapMap I+II project. To account for
the uncertainty of imputation, instead of using the ‘‘best guess’’
genotype for each individual, the additive dosage of the allele from
0 to 2, which is a weighted sum of the genotypes multiplied by
their estimated probability, was used to perform association tests
(MACH2QTL package). The ratio of the empirically observed
dosage variance (from the imputed genotypes) to the expected
(under binomial distribution) dosage variance (computed from the
estimated minor allele frequency) was estimated for every SNP as a
quality score for imputation. SNPs with the variance ratio ,0.3
were excluded.
Age, gender and the distributions of phenotypes are shown in
Table S1. Hip structural analysis measurements were done as
described previously [66]. Sex-specific standardized residuals of
phenotypes were calculated using general linear regression models
adjusted for age, age2, height (for hip geometry only), and BMI (for
hip geometry only). A linear regression model with additive genetic
effect was used to estimate p-values for single SNP GWAS. The
lGC for each trait ranged from 0.98 to 1.06, suggesting that there
was no major residual confounding by population stratification,
systematic genotyping error, or little evidence of cryptic related-
ness between individuals.
TwinsUK study. The TwinsUK cohort consists of
approximately 10,000 monozygotic (MZ) and dizygotic (DZ)
adult Caucasian twins aged 16 to 85 years recruited from the
general population all over the United Kingdom [67]. This study
was approved by the Research Ethics Committee of St. Thomas’
Hospital, and written informed consent was obtained from each
participant. BMD measurements (g/cm2) of the lumbar spine (L1–
L4) and femoral neck were performed by DXA using a Hologic
QDR 2000W densitometer (Hologic, Bedford, MA, USA). HSA
software developed by Beck et al. [53] was used to measure hip
geometry from the DXA scans as described in Framingham Study.
The genotyping methods and quality control have been described
previously [22]. In brief, 2,820 participants were genotyped by the
Hap300Duo, Hap300 or Hap550 SNP Infinium assay (Illumina,
San Diego, CA, USA). For potential population substructures, the
STRUCTURE program was used to assess participants’ ancestry
genetic background [68]. After excluding 14 outliers (individuals)
that lay outside the CEPH cluster from STRUCTURE analysis,
the lGC for the distribution of test statistic of BMD and hip
geometry ranged from 0.99 to 1.02, suggesting that there was no
residual confounding by population stratification, nor any
apparent systematic genotyping error, and little evidence of
cryptic relatedness. IMPUTE [69] was used to impute all
autosomal SNPs in the HapMap I+II project based on Map
(release 22, build 26, CEU population) reference panel. The ‘‘best-
guess’’ imputed genotypes were used in analyses. For each SNP, a
confidence score was calculated as the average of the maximum
posterior probabilities of the imputed genotypes. Individual
genotypes with confidence score less than 0.9 were excluded.
2,734 women with both BMD and genotypes were in the final
analyses (Table S1); however the sample size was smaller for HSA
as these measurements have not been completed in all cohort
members. Standardized residuals of phenotypes were calculated
using general linear regression models adjusted for age, age2,
height (for hip geometry only), and BMI (for hip geometry only). A
score test implemented in MERLIN [70] was used to estimate p-
values for single SNP analyses. An additive genetic effect model
was tested.
Joint analysis using fixed effect meta-analysis
model. We combined results from Framingham, Rotterdam
and TwinsUK studies using inverse-variance fixed effect meta-
analysis approaches to estimate combined p-values. The METAL
program (http://www.sph.umich.edu/csg/abecasis/Metal/) was
used. All association results were expressed relative to the forward
strand of the reference genome based on HapMap (dbSNP126).
The Cochran’s Q heterogeneity test across studies was also
estimated. Cochran’s Q p-values less than 0.05 indicate large
heterogeneity beyond chance. However, since only 2 or 3 cohorts
were meta-analyzed, there was insufficient number of studies for
the Q -statistics to be accurate calculated.
Multiple-testing. Recent GWAS have used different
genome-wide significant thresholds in between 561027 and
561028 [71–76]. Several GWAS on multiple correlated traits
GWAS and Expression Profiling for Osteoporosis
PLoS Genetics | www.plosgenetics.org 12 June 2010 | Volume 6 | Issue 6 | e1000977
estimated the genome-wide significant thresholds by FDR
[73–76]. We performed gender-specific GWAS on 5 correlated
traits (LS BMD, FN BMD, NSA, NL and NW). Since the pair-
wise genetic correlation is 0.7 between LSBMD and FNBMD,
Bonferroni correction for multiple testing is considered too
conservative for correlated association tests. Therefore, we
estimated genome-wide significant threshold by false discovery
rate (FDR) [77]. A total of 4,336,025 association tests were
performed in the discovery stage and in the meta-analysis
replication stage. We then estimated the q-value (positive false-
discovery rate) of each association test [78]. Based on the q-value
and the number of significant tests (defined as an association test
with q-value less than a particular q-value cutoff), we estimated the
maximum number of false associations at each q-value cutoff. We
set up the threshold for genome-wide significance of p-values as
4.361027, and this threshold resulted in #1 expected false
discovery of genome-wide significant association tests in our
GWAS. The corresponding q-value is 0.011.
Expression Profiling (Stage III): Human Tissues
We conducted expression quantitative trait locus (eQTL)
analysis to evaluate whether the genome-wide significant SNPs
for each locus also influence transcript levels of nearby genes as a
cis-effect regulator (eSNP) in human primary osteoblasts, lympho-
cytes and liver tissue. In each locus, we selected nearby genes in
which the genome-wide significant SNP was located within
500 Kb in the 59 upstream of candidate genes with the assumption
that SNPs are located in (or in LD with the variants located in)
regulation elements of candidate genes. Expression experiments in
primary osteoblasts, lymphocytes and liver tissues were conducted
in three different study samples. For un-genotyped SNPs, imputed
SNPs (MACH variance ratio .0.3) were used in the lymphocyte
expression dataset and surrogate SNPs with LD r2$0.5 were used
in primary osteoblasts and liver tissue datasets.
Primary osteoblasts. A gene expression profile with 18,144
known genes (Illumina Human Ref8v2 BeadChips) and genome-
wide genotyping of 561,303 SNPs (Illumina 550k Duo chips) were
available in 95 human Caucasian primary osteoblast samples.
Human trabecular bone from the shaft of proximal femora
obtained from donors undergoing total hip replacement. Primary
osteoblasts were derived from bone tissue. Tissue collection, RNA
and DNA isolation, expression profiling, and DNA genotyping
have been described in detail [79]. All gene expression levels were
adjusted for sex and year of birth. We studied the cis-expression
quantitative trait loci (cis-eQTL) of genome-wide significant SNPs
or their proxy (eSNP) with selected transcripts within 500 kb of the
SNP position. The linear regression model implemented in
PLINK [63] was used to determine association between adjusted
expression levels and genotypes.
Lymphocytes. Expression experiments in two different
samples were performed. A gene expression profile with 20,599
genes (Affymetrix U133 Plus 2.0) and genome-wide genotyping of
408,273 SNPs (Illumina HumanHap300 Genotyping Beadchip)
were available on 400 children from families recruited through a
proband with asthma. The detailed study design was described
elsewhere [9]. We also profiled expression levels using the Illumina
Human 6 BeadChips on additional 550 children from the UK
(recruited from families with atopic dermatitis probands). These
individuals were genotyped using Illumina HumanHap300
Genotyping Beadchip. Inverse normal transformation was used
to normalize the skewed distribution in both samples. MACH [64]
was used to impute un-genotyped SNPs based on Phase II
HapMap CEU panel. Association analysis was applied with
FASTASSOC option implemented in MERLIN [80]. Only cis-
effects within 500 Kb of the transcript were tested.
Liver tissue. A gene expression profile with 34,266 known
genes (Agilent custom array) and genome-wide genotyping of
782,476 SNPs (Affymetrix 500K and Illumina 650Y SNP
genotyping arrays) were available on 957 human Caucasian liver
samples. Liver samples were either postmortem or surgical
resections from organ donors. Tissue collection, RNA and DNA
isolation, expression profiling, and DNA genotyping have been
described previously [12]. All gene expression levels were adjusted
for age, sex, race, and center. We studied the cis-eQTL of
genome-wide significant SNP or its proxy (eSNP) with selected
transcripts within 500 kb of the SNP position. The Kruskal-Wallis
test was used to determine association between adjusted expression
levels and genotypes.
Expression Profiling (Stage III): Animal Models
Experiment 1: PTH stimulated gene expression profiling
of mouse primary osteoblasts. Primary osteoblastic cultures
were obtained from 2–3 day-old wild type C57BL/6J neonatal
mice calvariae, half samples from males and half from females.
Osteoblastic cell culture and PTH treatments were described
elsewhere [81]. The 48-hour treatment cycle (incubation in
medium with PTH for 6 hours, and incubation for the next
42 hours in medium without PTH) was repeated for 2 weeks. Cells
were harvested and total RNA was isolated at day 14, after the last
6 hours of PTH exposure. Triplicate arrays were run for each
condition/treatment with Affymetrix Mouse Genome 430A 2.0
arrays (approximately 14,000 genes per chip). Differences in gene
expression levels between PTH and vehicle samples were
evaluated. PTH-regulated genes were defined as follows: i) gene
expression was detectable in all 3 PTH- and/or 3 vehicle-treated
samples, ii) the average level of gene expression in PTH-treated
samples was at least 1.5-fold higher or lower than in vehicle-
treated samples, iii) gene expression levels differed by $1.5 fold
between PTH and vehicle-treated samples in at least 7 out of 9
comparisons (each PTH-treated sample compared to vehicle-
treated sample).
Experiment 2: Differential expression during osteoblast
maturation. To determine whether the top associated genes
were differentially expressed in maturing osteoblasts, we analyzed
gene expression profiles of D3 murine embryonic stem cells that
were undergoing directed differentiation toward the osteoblast
lineage by treatment with vitamin D3, b-glycerophosphate and
ascorbic acid. The gene expression dataset is publicly accessible via
Gene Expression Omnibus, NCBI (GEO accession GSE3792).
Gene expression patterns were generated using Affymetrix Mouse
Genome 430A arrays at seven time points (Day 4, 5, 6, 8, 16, 25
and 30 post-induction). Triplicate arrays were run for each time
point. The arrays were processed using the R AFFY package [82].
The robust multi-array average (RMA) algorithm was used for
normalization [83]. ANOVA was used to identify genes whose
expression differed across time points.
Experiment 3: Likelihood-based causality model
selection. To identify causal relationships for the top
associated genes discovered in our GWAS, we used the
likelihood-based causality model selection (LCMS) algorithm by
incorporating information of genotype, expression, and clinical
traits together to construct regulatory networks. The description of
the cross, genotyping and gene expression analysis have been
described previously [12,84]. The expression data is available via
NCBI’s Gene Expression Omnibus (GEO) database for adipose
(GSE11065), liver (GSE11338) and muscle (GSE12795) tissues.
The trabecular density measurement of the L5 vertebra from each
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F2 mouse was determined using a desktop mCT imaging system
(mCT 40; Scanco Medical, Bassersdorf, Switzerland). The
trabecular region was defined by contouring the inner section of
the vertebral body with exclusion of the growth plate. Quantitative
measurements of bone volume fraction (BV/TV), trabecular
number (TbN), trabecular thickness (TbTh), trabecular separation
(TbSp), mineral density of the bone volume fraction (DBV) and
total femoral areal BMD (BMD) from mice were calculated using
the Scanco software. mCT-derived trabecular bone data were
evaluated against a hydroxyapatite standard in the same setting.
LCMS procedure has been previously described [13,31]. LCMS
has been shown capable of recovering known causal relationships
and we recently validated this approach by characterizing
transgenic or knockout mouse models for 10 genes predicted
causal for obesity by LCMS, seven of which significantly affected
fat mass [85]. LCMS requires evidence of significant pleiotropy of
eQTL/clinical trait QTL pairs using a likelihood modeling to test
the fit of pleiotropy versus close linkage models. Three potential
models were tested including: 1) Causal model: DNA variation
affects a gene’s expression which affects a clinical trait; 2) Reactive
model: DNA variation affects a clinical trait which affects a gene’s
expression; and 3) Independent model: DNA variation
independently affects both a gene’s expression and clinical trait.
The model with the lowest Bayesian Information Criteria (BIC)
deemed the best fit. Reliability of each model call was determined
by repeating LCMS on 1000 bootstrap samples. Candidate genes
with at least 2 significant pleiotropy for eQTL and trait QTL pairs
were considered to be causally related to differences in bone-
related traits.
Experiment 4: Embryonic mouse in vivo gene expression
atlas database. To determine where and when genes in the
genome are expressed in the developing embryo in vivo [86], we
ascertained the anatomic locations that genes were expressed during
embryonic development in E10.5 and E14.5 wild type murine
embryos from EURExpress database. Gene expression profiling on
whole mounts and tissue sections of murine embryos were carried
out by RNA in-situ hybridization with non-radioactive probes. Level
and pattern of expression within each single organ or region are
scored according to a standard scheme. Three different levels of
expression were defined as (A) weak expression, (B) medium
expression, and (C) strong expression. If no colored precipitate is
seen, the gene expression is not detectable [87].
Prioritization of genome-wide suggestive candidate
genes. To prioritize candidate genes from the list of suggestive
genome-wide associated SNPs for further functional validation, we
selected 109 suggestive candidate genes in which SNPs located
within those regions were required to have all of the following
criteria: (1) meta-analysis p-values of association test in the range of
4.361027,p#561025, (2) p-values from the discovery stage
,1023, (3) p-values #0.05 from the replication stage and (4) the
same direction of effect from both discovery and replication stages.
We then prioritized these candidate genes based on results from
either (1) two significant results supported by three expression
signature profiles including PTH regulated genes (+++) from
experiment 1, differentiated expression during osteoblast
maturation (p,4.5961024, Bonferroni correction for 109 tests)
from experiment 2 and at least moderate expression in skeletal
sites of mouse embryos from experiment 4; or (2) candidate genes
with at least 2 pairs of significantly pleiotropic QTL/eQTL effects
from LCMS modeling (experiment 3).
Bioinformatic Approaches (Stage IV)
Gene-set enrichment tests on functional similarity. To
explore functional similarity of our prioritized associated genes,
we performed a gene-set enrichment test to examine the
probability of our candidate genes clustering in particular
biological/functional pathways as defined by the Gene
Ontology (GO) project [88]. The GO Consortium provides
controlled vocabularies, which model ‘‘Biological Process’’,
‘‘Molecular Function’’ and ‘‘Cellular Component’’ that are
structured into directed acyclic graphs based on published
literature and databases. Gene products may be annotated to
one or more GO nodes. To determine whether any GO terms
annotate a specified list of genes at a frequency greater than that
would be expected by chance, a p-value was calculated using the
hyper-geometric distribution [89]. To correct for multiple testing,
false discovery rate (FDR) was estimated [77].
Gene-set enrichment tests on expression abundance in
human tissues. It has been well accepted that the content of
the expressed sequence tag (EST) pool for a given tissue type
reflects the composition of original mRNA samples used for
creation of the complementary DNA library [90]. We estimated
gene expression abundance for our top associated genes in an
EST cDNA library (48 types of human normal tissues
and organs) from the Cancer Genome Anatomy Project,
National Cancer Institute (http://cgap.nci.nih.gov/Tissues).
We estimated the expected expression levels and performed
hyper-geometric tests to evaluate over- or under-representation
of individual genes in selected tissues, including bone, liver,
muscle and adipose tissue.
Supporting Information
Figure S1 Observed and expected expression levels (number of
EST sequences) in human bone and liver tissues from cDNA
Library. * 10210#p,0.0017; ** 10220#p,10210; *** p,10220.
Found at: doi:10.1371/journal.pgen.1000977.s001 (0.46 MB TIF)
Figure S2 Observed and expected expression levels (number of
EST sequences) in human muscle and adipose tissues from cDNA
Library. * 10210#p,0.0017; ** 10220#p,10210; *** p,10220.
Found at: doi:10.1371/journal.pgen.1000977.s002 (0.42 MB TIF)
Figure S3 Relative transcript levels (standardized residuals) in
human liver tissue for top associated candidate genes (from meta-
analysis) by genotype of top associated SNPs (or proxy) in Table 2.
Found at: doi:10.1371/journal.pgen.1000977.s003 (0.19 MB TIF)
Table S1 Descriptive characteristics of study participants by
Cohorts.
Found at: doi:10.1371/journal.pgen.1000977.s004 (0.02 MB
XLS)
Table S2 SNPs with association test p-value ,1.0E-06 in the
Framingham Study.
Found at: doi:10.1371/journal.pgen.1000977.s005 (0.02 MB
XLS)
Table S3 Molecular and functional characteristics of the
selected candidate genes in each region reported in Table 2.
Found at: doi:10.1371/journal.pgen.1000977.s006 (0.02 MB
XLS)
Table S4 Genes were predicted to be causally linked with bone
phenotypes using the Likelihood-based Causality Model (LCMS).
Found at: doi:10.1371/journal.pgen.1000977.s007 (0.02 MB
XLS)
Table S5 Molecular and functional characteristics of the
selected candidate genes in each region reported in Table 4.
Found at: doi:10.1371/journal.pgen.1000977.s008 (0.03 MB
XLS)
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